Excess Treatment-Related Mortality in Obese Children and Adolescents with Acute Myeloid Leukemia on AAML0531: A Report from the Children's Oncology Group

被引：1
|
作者：
Sung, Lillian [1 ]
Gerbing, Robert [2 ]
Alonzo, Todd A. [3 ]
Wang, Yi-Cheng [2 ]
Orgel, Etan [4 ]
Gamis, Alan S. [5 ]
Aplenc, Richard [6 ]
机构：
[1] Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Toronto, ON, Canada
[2] Childrens Oncol Grp, Monrovia, CA USA
[3] Univ So Calif, Keck Sch Med, Los Angeles, CA USA
[4] Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood Dis, Los Angeles, CA USA
[5] Childrens Mercy Hosp & Clin, Div Hematol Oncol Bone Marrow Transplantat, Kansas City, MO USA
[6] Childrens Hosp Philadelphia, Div Oncol & Ctr Childhood Canc Res, Philadelphia, PA USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2790.2790
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2790
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [21] CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531
    Lamba, Jatinder K.
    Chauhan, Lata
    Shin, Miyoung
    Loken, Michael R.
    Pollard, Jessica A.
    Wang, Yi-Cheng
    Ries, Rhonda E.
    Aplenc, Richard
    Hirsch, Betsy A.
    Raimondi, Susana C.
    Walter, Roland B.
    Bernstein, Irwin D.
    Gamis, Alan S.
    Alonzo, Todd A.
    Meshinchi, Soheil
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2674 - +
  • [22] A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531
    Brodersen, Lisa Eidenschink
    Alonzo, Todd A.
    Menssen, Andrew J.
    Gerbing, Robert B.
    Pardo, Laura
    Voigt, Andrew P.
    Kahwash, Samir B.
    Hirsch, Betsy A.
    Raimondi, Susana C.
    Gamis, Alan S.
    Meshinchi, Soheil
    Loken, Michael R.
    BLOOD, 2015, 126 (23)
  • [23] Treatment-Related Acute Myeloid Leukemia in Children
    Waack, Katharina
    Roellecke, Katharina
    Rasche, Mareike
    Walter, Christiane
    Creutzig, Ursula
    Reinhardt, Dirk
    BLOOD, 2019, 134
  • [24] CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial
    Lamba, Jatinder
    Chauhan, Lata
    Shin, Miyoung
    Loken, Michael R.
    Pollard, Jessica A.
    Wang, Jim
    Aplenc, Richard
    Hirsch, Betsy A.
    Raimondi, Susana C.
    Walter, Roland B.
    Bernstein, Irwin D.
    Gamis, Alan S.
    Alonzo, Todd A.
    Meshinchi, Soheil
    BLOOD, 2017, 130
  • [25] Treatment of 11q23/MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase Ill Children's Oncology Group Trial AAML0531
    Pollard, Jessica
    Alonzo, Todd A.
    Cerbing, Robert B.
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Sung, Lillian
    Aplenc, Richard
    Guest, Erin M.
    Bernstein, Irwin D.
    Loken, Michael R.
    Meshinchi, Soheil
    Gamis, Alan S.
    BLOOD, 2015, 126 (23)
  • [26] High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group
    Sung, Lillian
    Alonzo, Todd A.
    Gerbing, Robert B.
    Aplenc, Richard
    Meshinchi, Soheil
    Burden, Laura
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Kahwash, Samir
    Heerema-McKenney, Amy
    Winter, Laura
    Glick, Kathleen
    Byron, Patti
    Wallas, Tanya
    Smith, Franklin O.
    Gamis, Alan S.
    BLOOD, 2010, 116 (21) : 468 - 469
  • [27] Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report
    Getz, Kelly D.
    Miller, Tamara P.
    Seif, Alix E.
    Li, Yimei
    Huang, Yuan-Shung
    Alonzo, Todd
    Gerbing, Robert
    Sung, Lillian
    Hall, Matthew
    Bagatell, Rochelle
    Gamis, Alan
    Fisher, Brian T.
    Aplenc, Richard
    CANCER MEDICINE, 2016, 5 (09): : 2412 - 2416
  • [28] Heirarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531
    Loken, Michael R.
    Voigt, Andrew P.
    Gerbing, Robert B.
    Brodersen, Lisa Eidenschink
    Menssen, Andrew J.
    Pardo, Laura
    Gamis, Alan S.
    Alonzo, Todd A.
    Meshinchi, Soheil
    BLOOD, 2015, 126 (23)
  • [29] Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk - Results From The Randomized Phase III Children's Oncology Group (COG) Trial, AAML0531
    Gamis, Alan S.
    Aplenc, Richard
    Alonzo, Todd A.
    Sung, Lillian
    Meshinchi, Soheil
    Gerbing, Robert B.
    Raimondi, Susana C.
    Hirsch, Betsy
    Kahwash, Samir
    McKenney, Amy Heerema
    Winter, Laura
    Glick, Kathleen
    Davies, Stella M.
    Byron, Patti
    Smith, Franklin O.
    BLOOD, 2013, 122 (21)
  • [30] Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial
    Taub, Jeffrey W.
    Berman, Jason N.
    Hitzler, Johann K.
    Sorrell, April D.
    Lacayo, Norman J.
    Mast, Kelley
    Head, David
    Raimondi, Susana
    Hirsch, Betsy
    Ge, Yubin
    Gerbing, Robert B.
    Wang, Yi-Cheng
    Alonzo, Todd A.
    Campana, Dario
    Coustan-Smith, Elaine
    Mathew, Prasad
    Gamis, Alan S.
    BLOOD, 2017, 129 (25) : 3304 - 3313
12345